Download PDF
Semin Liver Dis 2004; 24: 77-82
DOI: 10.1055/s-2004-828682
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

New Treatment of Chronic Hepatitis B

Anna S. F. Lok1
  • 1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
11 June 2004 (online)

    Permissions and Reprints

Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance. Thus, new treatments that have more potent antiviral effects, less toxicity, and minimal or no risk of resistance are needed. This article will focus on new antiviral agents that are being evaluated in clinical trials.

KEYWORDS

Entecavir - emtricitabine - clevudine - telbivudine - tenofovir

REFERENCES

  • 1 Seifer M, Hamatake R K, Colonno R J, Standring D N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.  Antimicrob Agents Chemother. 1998;  42 3200-3208
    PubMedGoogle Scholar
  • 2 Ono S, Kato N, Shiratori Y et al.. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.  J Clin Invest. 2001;  107 449-455
    PubMedGoogle Scholar
  • 3 Colonno R, Genovesi E, Medina I et al.. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.  J Infect Dis. 2001;  184 1236-1245
    CrossrefPubMedGoogle Scholar
  • 4 Marion P, Salazar F, Winters M, Colonno R. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.  Antimicrob Agents Chemother. 2002;  46 82-88
    CrossrefPubMedGoogle Scholar
  • 5 Lai C L, Rosmawati M, Lao J et al.. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.  Gastroenterology. 2002;  123 1831-1838
    CrossrefPubMedGoogle Scholar
  • 6 Chang T, Hadziyannis S, Cianciara J et al.. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.  Hepatology. 2002;  36 300A
    PubMedGoogle Scholar
  • 7 Shakil A, Lilly L, Angus P et al.. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection.  J Hepatol. 2002;  36(Suppl 1) 122
    PubMedGoogle Scholar
  • 8 Le Guerhier F, Pichoud C, Guerret S et al.. Characterization of the antiviral effect of 2',3′-dideoxy-2', 3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.  Antimicrob Agents Chemother. 2000;  44 111-122
    PubMedGoogle Scholar
  • 9 Gish R G, Leung N W, Wright T L et al.. Anti-hepatitis B virus (HBV) activity and pharmacokinetics of FTC in a 2 month trial in HBV infected patients.  Gastroenterology. 1999;  116 A1216
    PubMedGoogle Scholar
  • 10 Gish R, Leung N, Wang C et al.. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years.  Hepatology. 2002;  36 372A
    PubMedGoogle Scholar
  • 11 Liaw Y F, Leung N W, Chang T T et al.. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.  Gastroenterology. 2000;  119 172-180
    CrossrefPubMedGoogle Scholar
  • 12 Balakrishna Pai S, Liu S H, Zhu Y L, Chu C K, Cheng Y C. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.  Antimicrob Agents Chemother. 1996;  40 380-386
    PubMedGoogle Scholar
  • 13 Peek S F, Cote P J, Jacob J R et al.. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-β, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).  Hepatology. 2001;  33 254-266
    CrossrefPubMedGoogle Scholar
  • 14 Marcellin P, Sacks S, Lau G KK et al.. A dose-escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection.  Gastroenterology. 2003;  124 A709
    PubMedGoogle Scholar
  • 15 Bryant M, Bridges E, Placidi L et al.. Antiviral L-nucleosides specific for hepatitis B virus infection.  Antimicrob Agents Chemother. 2001;  45 229-235
    CrossrefPubMedGoogle Scholar
  • 16 Tennant B, Meene S, Baldwin B et al.. Antiviral activities of beta-L-thymidine (LdT), val-beta-L-2'-deoxycytidine (val-LdC), and lamivudine alone and in combination in a 12 week, oral dose study using the woodchuck model of chronic hepatitis B virus infection. Antiviral Research. HEP DART 2001.  Frontiers in Drug Development for Viral Hepatitis. 2001;  32 A27
    PubMedGoogle Scholar
  • 17 Lai C, Lam P, Myers M et al.. Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): results of a dose-escalation trial.  Hepatology. 2001;  34 321A
    PubMedGoogle Scholar
  • 18 Lai C, Leung N, Teo E K et al.. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B.  Hepatology. 2003;  38 262A
    PubMedGoogle Scholar
  • 19 Lim S, Lai C, Dan Y et al.. Val-LdC: first evidence of efficacy and safety for a new anti-HBV agent.  Gastroenterology. 2002;  A628
    PubMedGoogle Scholar
  • 20 Lin T, Luo M, Liu M et al.. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.  J Med Chem. 1996;  39 1757-1759
    CrossrefPubMedGoogle Scholar
  • 21 Afdal N, O'Brien C, Oshana S, Dunkle L. Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: predictions for activity against YMDD mutant strains.  Hepatology. 2002;  36 372A
    PubMedGoogle Scholar
  • 22 Ying C, De Clercq E, Nicholson W et al.. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.  J Viral Hepat. 2000;  7 161-165
    CrossrefPubMedGoogle Scholar
  • 23 Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.  N Engl J Med. 2003;  348 177-178
    CrossrefPubMedGoogle Scholar
  • 24 van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.  Hepatology. 2002;  36 507-508
    CrossrefPubMedGoogle Scholar
  • 25 Nelson M, Portsmouth S, Stebbing J et al.. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals.  AIDS. 2003;  17 F7-F10
    CrossrefPubMedGoogle Scholar
  • 26 Nunez M, Perez-Olmeda M, Diaz B et al.. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.  AIDS. 2002;  16 2352-2354
    CrossrefPubMedGoogle Scholar
  • 27 Ristig M, Crippin J, Aberg J et al.. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed.  J Infect Dis. 2002;  186 1844-1847
    CrossrefPubMedGoogle Scholar
  • 28 van Bommel F, Wunsche T, Schurmann D et al.. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection.  Hepatology. 2003;  38 275A
    PubMedGoogle Scholar
  • 29 Schooley R, Ruane P, Myers R et al.. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.  AIDS. 2002;  16 1257-1263
    PubMedGoogle Scholar
  • 30 Verheist D, Monge M, Meynard J L et al.. Fanconi syndrome and renal failure induced by tenofovir: a first case report.  Am J Kidney Dis. 2002;  40 1331-1333
    CrossrefPubMedGoogle Scholar

Anna S F LokM.D. 

Division of Gastroenterology, University of Michigan Medical Center

3912 Taubman Center, Box 0362, Ann Arbor, MI 48109

Email: aslok@umich.edu

      >